Evaluation of respiratory model employing conventional NIH mice to access the immunity induced by cellular and acellular pertussis vaccines.
The increasing number of pertussis cases reported on the last twenty years and the existence of new acellular vaccines reinforce the need of research for experimental models to assure the quality of available pertussis vaccines. In this study, allotments of whole-cell and acellular pertussis vaccines were tested through the Intranasal Challenge Model (INM) using conventional NIH mice. The results have been compared to those achieved by the "Gold standard" Intracerebral Challenge Model (ICM). In contrast to ICM, INM results did not show intralaboratorial variations. Statistical analysis by Anova and Ancova tests revealed that the INM presented reproducibility and allowed identification and separation of different products, including three-component and four-component accellular pertussis vaccines. INM revealed differences between pertussis vaccines. INM provides lower distress to the mice allowing the reduction of mice number including the possibility of using conventional mice (less expensive) under non-aseptic environment. Thus, INM may be used as an alternative method of verifying the consistence of allotment production, including acellular pertussis vaccines.
Dias
Alexandre Alves de Souza de Oliveira
AA
Laboratório de Vacinas Bacterianas, Departamento de Imunologia, Instituto Nacional de Controle de Qualidade em Saúde, Fiocruz, 21040-900 Rio de Janeiro, RJ, Brazil. alexandre.dias@incqs.fiocruz.br
Boller
Maria Aparecida Affonso
MA
Werneck
Lúcia Maria Correa
LM
Hirata Junior
Raphael
R
Mattos-Guaraldi
Ana Luíza
AL
D000281:Administration, Intranasal; D000818:Animals; D001886:Bordetella pertussis / Q000276:immunology*; D004195:Disease Models, Animal; D005260:Female; D007111:Immunity, Cellular; D008297:Male; D051379:Mice; D010567:Pertussis Vaccine / Q000009:adverse effects / Q000276:immunology* / Q000592:standards; D015203:Reproducibility of Results; D013997:Time Factors; D022282:Vaccines, Acellular / Q000009:adverse effects / Q000276:immunology / Q000592:standards; D014614:Vaccines, Synthetic / Q000009:adverse effects / Q000276:immunology / Q000592:standards; D014917:Whooping Cough / Q000276:immunology* / Q000517:prevention & control
D010567:Pertussis Vaccine; D022282:Vaccines, Acellular; D014614:Vaccines, Synthetic